AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16679811 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 146
Study 16679811 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 146
Study 15324486 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-29 (3.0 g thrice daily for 7 days)
Number of subjects: 26
Study 15324486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11227677 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-I (6 weeks of 'A' formulation of omeprazole [20 mg twice daily] plus 2 weeks of amoxicillin [1.0 g twice daily] and clarithromycin [500 mg twice daily])
Number of subjects: 74
Study 11227677 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-II (6 weeks of 'B' formulation of omeprazole [20 mg twice daily] plus 2 weeks of the same antibiotics)
Number of subjects: 74
Study 11227677 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-I
Number of subjects: 74
Study 11227677 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-II
Number of subjects: 74
Study 9286938 — intervention group
Group type: EXPERIMENTAL
Intervention: xemilofiban 10 mg P.O. BID or higher
Number of subjects: 170
Study 9286938 — intervention group
Group type: COMPARATOR
Intervention: placebo (250 mg ticlopidine P.O. BID)
Number of subjects: 170
Study 8326539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (150,000 units IM on day 1 followed by 15,000 units orally for 7 days)
Number of subjects: 0
Study 8326539 — intervention group
Group type: COMPARATOR
Intervention: Routine appropriate treatment (may include 3000 units vitamin A per day)
Number of subjects: 0
Study 3553492 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and stress-management training
Number of subjects: 0
Study 3553492 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31992840 — intervention group
Group type: EXPERIMENTAL
Intervention: IL7Rp mutated (IL7Rpmut) T-ALL
Number of subjects: 200
Study 31992840 — intervention group
Group type: COMPARATOR
Intervention: IL7Rp non-mutated (IL7RpWT) T-ALL
Number of subjects: 200
Study 31992840 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 200
Study 31992840 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-induction chemotherapy regimens
Number of subjects: 200
Study 30943878 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery plus thrombolysis
Number of subjects: 500
Study 30943878 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 500
Study 28320081 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 209
Study 28320081 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (WL) camp
Number of subjects: 209
Study 28320081 — intervention group
Group type: COMPARATOR
Intervention: Residential intermittent programme
Number of subjects: 209
Study 28320081 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient programme
Number of subjects: 209
Study 25425058 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine 20 mg/day
Number of subjects: 104
Study 25425058 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10 mg/day
Number of subjects: 104
Study 23462586 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamins and antioxidant vitamins (n = 50)
Number of subjects: 100
Study 23462586 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 100
Study 21911597 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg
Number of subjects: 0
Study 21911597 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 19372098 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 1352
Study 19372098 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 1352
Study 16329161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg per day)
Number of subjects: 197
Study 16329161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 15570185 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy for MPA
Number of subjects: 136
Study 11333838 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration
Number of subjects: 27
Study 11333838 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous weight gain
Number of subjects: 27
Study 9203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated varicella vaccine (3625 pfu)
Number of subjects: 0
Study 9203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially heat-inactivated vaccine (1125 pfu)
Number of subjects: 0
Study 9203669 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially heat-inactivated vaccine (439 pfu)
Number of subjects: 0
Study 9203669 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8213445 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25
Study 3677376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (group A)
Number of subjects: 20
Study 3677376 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group B)
Number of subjects: 20
Study 30730838 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 120
Study 30730838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (nature sounds + reflexology)
Number of subjects: 120
Study 30730838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 120
Study 30730838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27749154 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP+Myomo therapy (repetitive task-specific practice with myoelectric brace)
Number of subjects: 12
Study 27749154 — intervention group
Group type: COMPARATOR
Intervention: RTP only (repetitive task-specific practice)
Number of subjects: 12
Study 25748612 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (specific trials: JUPITER and ASCOT for primary prevention; CARE and PROVE IT‐TIMI 22 for secondary prevention)
Number of subjects: 48421
Study 25748612 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (specific trials: JUPITER and ASCOT for primary prevention)
Number of subjects: 48421
Study 25748612 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 48421
Study 22762723 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary team-based 'geriatric' care model by non-geriatrics specialist physicians
Number of subjects: 0
Study 22762723 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21878743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus rapid-acting insulin analogues
Number of subjects: 10
Study 21878743 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with normal glucose tolerance
Number of subjects: 10
Study 18640810 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation with high-dose-rate brachytherapy (4 Gy twice a day for 4 days, total dose 32 Gy)
Number of subjects: 80
Study 18640810 — intervention group
Group type: COMPARATOR
Intervention: Patients implanted during surgery
Number of subjects: 80
Study 17563214 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 128
Study 17563214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15957245 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20 g/day for 5 days)
Number of subjects: 19
Study 15957245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12145915 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.4 mg/kg BW
Number of subjects: 329
Study 12145915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam 0.3 mg/kg BW
Number of subjects: 329
Study 12145915 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 329
Study 11913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + MPA 2.5 mg
Number of subjects: 568
Study 11913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + MPA 5.0 mg
Number of subjects: 568
Study 11913409 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + MPA 10 mg
Number of subjects: 568
Study 11913409 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 568
Study 8029670 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 565
Study 2685142 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (5 KE, administered by intramuscular injection every other day for up to 5 years)
Number of subjects: 215
Study 2685142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 215
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual romantic films
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sex mild (two males and one female)
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual genital films
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sex explicit (three males and three females)
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadomasochism mild
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadomasochism explicit (forcing and brutal)
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Male homosexuality
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ratings of group sex films and rejection of sexual myths
Number of subjects: 20
Study 943472 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between rated degree of sexual stimulation for heterosexual and group sex films
Number of subjects: 20
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dose <70 U/kg
Number of subjects: 0
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dose 70-100 U/kg
Number of subjects: 0
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dose >100 U/kg
Number of subjects: 0
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT <250 s
Number of subjects: 0
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT 250-350 s
Number of subjects: 0
Study 31093662 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT >350 s
Number of subjects: 0
Study 31472360 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless CRT system (therapy on)
Number of subjects: 350
Study 31472360 — intervention group
Group type: COMPARATOR
Intervention: Sham control (therapy off)
Number of subjects: 350
Study 27933333 — intervention group
Group type: EXPERIMENTAL
Intervention: BCF indices (I30/I0, CP30/CP0, ΔI30/ΔG30, ΔCP30/ΔG30, corrected insulin response at 30 min) for incident type 2 diabetes
Number of subjects: 476
Study 27933333 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposition indices (BCF index × Matsuda index)
Number of subjects: 476
Study 27933333 — intervention group
Group type: EXPERIMENTAL
Intervention: All ROC AUCs for incident prediabetes
Number of subjects: 476
Study 27933333 — intervention group
Group type: COMPARATOR
Intervention: Matsuda index
Number of subjects: 476
Study 25331843 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 126
Study 23842141 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL levels <40 mg/dL
Number of subjects: 113
Study 23842141 — intervention group
Group type: COMPARATOR
Intervention: HDL levels >40 mg/dL
Number of subjects: 113
Study 23842141 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL levels >60 mg/dL
Number of subjects: 113
Study 22187278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone-based stepped-care therapy (active treatment)
Number of subjects: 4736
Study 22187278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 19301378 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study 19301378 — intervention group
Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 0
Study 19301378 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 19301378 — intervention group
Group type: EXPERIMENTAL
Intervention: Other agents (cyclophosphamide, rituximab, azathioprine, cyclosporine, interferons, fludarabine, mycophenolate mofetil, etanercept)
Number of subjects: 0
Study 16269179 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1mg/kg/day for 10 days, followed by tapering over 4 days)
Number of subjects: 60
Study 16269179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (anti-epileptic monotherapy)
Number of subjects: 60
Study 15327804 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice a day
Number of subjects: 68
Study 15327804 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice a day
Number of subjects: 68
Study 15327804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10654905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal alprostadil (EDEX)
Number of subjects: 111
Study 10654905 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral alprostadil (MUSE)
Number of subjects: 111
Study 9052354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐123‐metaiodobenzylguanidine (MIBG) scintigraphy
Number of subjects: 0
Study 8337465 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 185
Study 8337465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 185
Study 3896662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg/day)
Number of subjects: 30
Study 3896662 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (40 mg/day)
Number of subjects: 30
Study 29926653 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Qigong Baduanjin exercise for 24 weeks
Number of subjects: 40
Study 29926653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 27236412 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 30
Study 27236412 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 30
Study 25543612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic endo‐instruments in combination with Mtwo Ni‐Ti files
Number of subjects: 100
Study 25543612 — intervention group
Group type: COMPARATOR
Intervention: Stainless‐steel files
Number of subjects: 100
Study 21030367 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Assessment (TA)
Number of subjects: 70
Study 21030367 — intervention group
Group type: COMPARATOR
Intervention: Assessment as Usual (AAU)
Number of subjects: 70
Study 16200755 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot devices for wrist rehabilitation (G1)
Number of subjects: 16
Study 16200755 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot devices for elbow-shoulder rehabilitation (G2)
Number of subjects: 16
Study 12207774 — intervention group
Group type: EXPERIMENTAL
Intervention: oral allopurinol (15 mg/kg/day) for 3 weeks
Number of subjects: 150
Study 12207774 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular injection of Glucantime (30 mg/kg/day) for 2 weeks
Number of subjects: 150
Study 12207774 — intervention group
Group type: EXPERIMENTAL
Intervention: combined therapy with allopurinol plus Glucantime
Number of subjects: 150
Study 9579010 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling + Active Nicotine Patch (CAP)
Number of subjects: 185
Study 9579010 — intervention group
Group type: COMPARATOR
Intervention: Counseling + Placebo Patch (CPP)
Number of subjects: 185
Study 9579010 — intervention group
Group type: COMPARATOR
Intervention: Minimal Care (MC)
Number of subjects: 185
Study 7698030 — intervention group
Group type: EXPERIMENTAL
Intervention: 55% carbohydrate diet
Number of subjects: 0
Study 2523720 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 38032F
Number of subjects: 0
Study 2523720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 0
Study 2523720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 0
Study 320916 — intervention group
Group type: EXPERIMENTAL
Intervention: clemastine fumarate 2.68 mg
Number of subjects: 48
Study 320916 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine 4 mg
Number of subjects: 48
Study 320916 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 29061540 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious digital rectal examination
Number of subjects: 35350
Study 29061540 — intervention group
Group type: COMPARATOR
Intervention: Normal prostate specific antigen (<2 ng/ml)
Number of subjects: 35350
Study 29061540 — intervention group
Group type: COMPARATOR
Intervention: Elevated prostate specific antigen (≥3 ng/ml)
Number of subjects: 35350
Study 29061540 — intervention group
Group type: COMPARATOR
Intervention: Equivocal prostate specific antigen (2-3 ng/ml)
Number of subjects: 35350
Study 27625085 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic total thyroidectomy with CND via bilateral axillo-breast approach (BABA)
Number of subjects: 100
Study 27625085 — intervention group
Group type: COMPARATOR
Intervention: Conventional open procedure
Number of subjects: 100
Study 25720440 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent urinary tract simulator (experimental group)
Number of subjects: 160
Study 25720440 — intervention group
Group type: COMPARATOR
Intervention: Opaque plastic urinary tract simulator (control group)
Number of subjects: 160
Study 24156019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone/prednisone/custirsen (MPC)
Number of subjects: 67
Study 24156019 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel retreatment/prednisone/custirsen (DPC)
Number of subjects: 67
Study 19911223 — intervention group
Group type: EXPERIMENTAL
Intervention: TT technique (2 trocars in the umbilicus)
Number of subjects: 32
Study 19911223 — intervention group
Group type: EXPERIMENTAL
Intervention: TT technique
Number of subjects: 32
Study 19911223 — intervention group
Group type: COMPARATOR
Intervention: ST technique (single-trocar)
Number of subjects: 32
Study 19911223 — intervention group
Group type: COMPARATOR
Intervention: ST technique
Number of subjects: 32
Study 17971715 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC and EFV
Number of subjects: 0
Study 17971715 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC and EFV
Number of subjects: 0
Study 16644630 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltec Cozmo insulin pump with meal bolus alarms (experimental group)
Number of subjects: 48
Study 16644630 — intervention group
Group type: COMPARATOR
Intervention: Current insulin pumps without meal bolus alarms (control group)
Number of subjects: 48
Study 12806326 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion with 50‐microm aluminum oxide
Number of subjects: 30
Study 12806326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydrofluoric acid etching
Number of subjects: 30
Study 12806326 — intervention group
Group type: COMPARATOR
Intervention: Control group (specimens without additional surface treatments)
Number of subjects: 30
Study 10992835 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure (Group C)
Number of subjects: 70
Study 10992835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham pressure (Group S)
Number of subjects: 70
Study 8976723 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 260
Study 8976723 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids without acyclovir
Number of subjects: 260
Study 8976723 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids and oral acyclovir
Number of subjects: 260
Study 1535485 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1% and alfentanil 10 micrograms.kg‐1 as a bolus and 10 micrograms.kg‐1.h‐1 infusion (group IA)
Number of subjects: 114
Study 1535485 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 9 mg.kg‐1.h‐1 infusion decreasing to 6 mg.kg‐1.h‐1 and alfentanil 10 micrograms.kg‐1.h‐1 (group PA)
Number of subjects: 114
Study 1535485 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (group IO)
Number of subjects: 114
Study 1535485 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group PO)
Number of subjects: 114
Study 1535485 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of 25 females (not anaesthetised)
Number of subjects: 114
Study 6747766 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 30
Study 6747766 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg plus Pancuronium 0.1 mg/kg
Number of subjects: 30
Study 6747766 — intervention group
Group type: COMPARATOR
Intervention: No medication (controls)
Number of subjects: 30
Study 6747766 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 30868125 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Number of subjects: 34
Study 30868125 — intervention group
Group type: COMPARATOR
Intervention: Medium Chain Triglycerides (MCTs)
Number of subjects: 34
Study 30942961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 1
Number of subjects: 48
Study 30942961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 2
Number of subjects: 48
Study 30942961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 3
Number of subjects: 48
Study 30942961 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 48
Study 30942961 — intervention group
Group type: COMPARATOR
Intervention: No Adhesive
Number of subjects: 48
Study 27658873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (multicomponent intervention)
Number of subjects: 12024
Study 27658873 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard of care)
Number of subjects: 12024